{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:34:32Z","timestamp":1792838072089,"version":"4.5.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Shanghai Municipal Health Commission of Science and Research Fund","award":["20184Y0289"],"award-info":[{"award-number":["20184Y0289"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>Is a dual ovulation trigger with a combination of GnRH agonist (GnRHa) and hCG superior to single hCG and\/or single GnRHa trigger in improving treatment outcomes in advanced-age women (aged \u2265 35\u2009years) undergoing IVF\/ICSI treatment?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>Co-administration of GnRHa and hCG as a dual trigger increases the number of good-quality embryos but it is not associated with a higher number of oocytes retrieved, compared with single hCG or GnRHa trigger.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>Many studies have demonstrated that a dual trigger has positive impact on oocyte maturation, retrieval rate and pregnancy rate without increasing the risk of ovarian hyperstimulation syndrome (OHSS) in some groups of IVF patients, when compared with single hCG trigger. Few studies have however been conducted to compare a dual trigger with a single GnRHa trigger, and insufficient evidence exists to support which trigger can achieve the best outcomes in IVF patients aged \u226535\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>This was an open-label randomized controlled trial of 510 participants conducted at single reproductive medical center from January 2019 to December 2021. After a sample size calculation performed by retrospectively analyzing our previous clinical data, we planned to recruit 170 patients in each group and 510 patients in total for the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Women aged \u226535\u2009years undergoing IVF\/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial. On the trigger day, patients were randomized into three groups: hCG alone (who received 6000\u2009IU of hCG), GnRHa alone (who received 0.2\u2009mg of triptorelin) and dual trigger (who received 0.2\u2009mg of triptorelin plus 2000\u2009IU of hCG) groups. The primary outcome parameter was the number of retrieved oocytes. The secondary outcome parameters included, among others, the number and rates of mature oocytes, two pronuclei (2PN) embryos and good-quality embryos, as the rates of OHSS, clinical pregnancy, miscarriage and live birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>There were no significant differences in the baseline demographic characteristics among the three groups. The dual trigger was associated with a higher retrieval rate (87.9% vs 84.1% in the hCG group, P\u2009=\u20090.031; 87.9% vs 83.6% in the GnRHa group, P\u2009=\u20090.014). However, the number of retrieved oocytes in the dual trigger group was comparable with those in the hCG group (4.08\u2009\u00b1\u20092.79 vs 3.60\u2009\u00b1\u20092.71, P\u2009=\u20090.080) and the GnRHa group (4.08\u2009\u00b1\u20092.79 vs 3.81\u2009\u00b1\u20093.38, P\u2009=\u20090.101); comparable data between the groups were also found when analyzing the number of 2PN embryos and the 2PN rate. In the dual trigger group, the numbers of good-quality embryos and viable embryos were both significantly higher than in the hCG group (1.74\u2009\u00b1\u20091.90 vs 1.19\u2009\u00b1\u20091.45, P\u2009=\u20090.016 and 2.19\u2009\u00b1\u20092.11 vs 1.56\u2009\u00b1\u20091.66, P\u2009=\u20090.008, respectively) and the GnRHa group (1.74\u2009\u00b1\u20091.90 vs 1.20\u2009\u00b1\u20091.67, P\u2009=\u20090.003 and 2.19\u2009\u00b1\u20092.11 vs 1.45\u2009\u00b1\u20091.75, P\u2009=\u20090.001, respectively). Pregnancy outcomes after fresh embryo transfer (ET) were comparable between the groups. The live birth rate and ongoing pregnancy rate after frozen ET in the dual trigger group were significantly higher than those in the GnRHa group (32.6% vs 14.1%, P\u2009=\u20090.007 and 34.8% vs 17.6%, P\u2009=\u20090.013, respectively), but not superior to those in the hCG group (32.6% vs 27.9%, P\u2009=\u20090.537 and 34.8% vs 27.9%, P\u2009=\u20090.358, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>Women of advanced age are quite a heterogeneous population and overlap with poor ovarian responders or patients with diminished ovarian reserve. We therefore could not entirely exclude selection biases or confounding factors. This study was also not a double-blinded trial; the patients in the GnRHa and dual trigger groups could have been affected by the placebo effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>The results of this study suggest that in advanced-age women with low risk of OHSS, a dual trigger or even a single hCG trigger may be a better choice than a single GnRHa trigger.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>This study was supported by the Shanghai Municipal Health Commission of Science and Research Fund (20184Y0289). The authors declare no conflict of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>This trial was registered in the Chinese Clinical Trial Registry (ChiCTR-1800016285).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION DATE<\/jats:title>\n                    <jats:p>24 May 2018<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATE OF FIRST PATIENT\u2019S ENROLMENT<\/jats:title>\n                    <jats:p>2 January 2019<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deac114","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T07:08:31Z","timestamp":1651907311000},"page":"1795-1805","source":"Crossref","is-referenced-by-count":51,"title":["Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF\/ICSI cycles"],"prefix":"10.1093","volume":"37","author":[{"given":"Chengliang","family":"Zhou","sequence":"first","affiliation":[{"name":"Reproductive Medical Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai, China"},{"name":"Shanghai Key Laboratory of Embryo Original Diseases , Shanghai, China"},{"name":"Shanghai Municipal Key Clinical Speciality , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Yang","sequence":"additional","affiliation":[{"name":"Reproductive Medical Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai, China"},{"name":"Shanghai Key Laboratory of Embryo Original Diseases , Shanghai, China"},{"name":"Shanghai Municipal Key Clinical Speciality , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[{"name":"Reproductive Medical Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai, China"},{"name":"Shanghai Key Laboratory of Embryo Original Diseases , Shanghai, China"},{"name":"Shanghai Municipal Key Clinical Speciality , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Xi","sequence":"additional","affiliation":[{"name":"Reproductive Medical Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Pan","sequence":"additional","affiliation":[{"name":"Reproductive Medical Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[{"name":"Reproductive Medical Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Reproductive Medical Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2503-3581","authenticated-orcid":false,"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[{"name":"Reproductive Medical Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai, China"},{"name":"Shanghai Key Laboratory of Embryo Original Diseases , Shanghai, China"},{"name":"Shanghai Municipal Key Clinical Speciality , Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"2022080105591424600_deac114-B1","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/humrep\/der037","article-title":"The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting","volume":"26","author":"Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology","year":"2011","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/humrep\/des037","article-title":"Empty follicle syndrome: successful treatment in a recurrent case and review of the literature","volume":"27","author":"Beck-Fruchter","year":"2012","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/01443615.2019.1674791","article-title":"Does \u2018dual trigger\u2019 increase oocyte maturation rate?","volume":"40","author":"Ben-Haroush","year":"2020","journal-title":"J Obstet Gynaecol"},{"key":"2022080105591424600_deac114-B4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.fertnstert.2007.11.049","article-title":"Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study","volume":"91","author":"Bodri","year":"2009","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/humrep\/15.10.2129","article-title":"Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series","volume":"15","author":"Casson","year":"2000","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00404-018-4751-3","article-title":"Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF\/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis","volume":"298","author":"Chen","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"2022080105591424600_deac114-B7","doi-asserted-by":"crossref","first-page":"e0235707","DOI":"10.1371\/journal.pone.0235707","article-title":"Dual-trigger improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve: a retrospective cohort study","volume":"15","author":"Chern","year":"2020","journal-title":"PLoS One"},{"key":"2022080105591424600_deac114-B8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","article-title":"Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review","volume":"8","author":"Delvigne","year":"2002","journal-title":"Hum Reprod Update"},{"key":"2022080105591424600_deac114-B9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.fertnstert.2009.10.034","article-title":"Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting","volume":"94","author":"DiLuigi","year":"2010","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejogrb.2017.09.004","article-title":"Dual trigger of final oocyte maturation with a combination of GnRH agonist and hCG versus a hCG alone trigger in GnRH antagonist cycle for in vitro fertilization: a systematic review and meta-analysis","volume":"218","author":"Ding","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2022080105591424600_deac114-B11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jcem.87.2.8197","article-title":"Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization","volume":"87","author":"Fauser","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2022080105591424600_deac114-B12","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1530\/JOE-16-0105","article-title":"Improvements in IVF in women of advanced age","volume":"230","author":"Gleicher","year":"2016","journal-title":"J Endocrinol"},{"key":"2022080105591424600_deac114-B13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.fertnstert.2006.12.006","article-title":"Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles","volume":"88","author":"Griesinger","year":"2007","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B14","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/humrep\/dem006","article-title":"Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study","volume":"22","author":"Griesinger","year":"2007","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.fertnstert.2012.03.015","article-title":"Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders","volume":"97","author":"Griffin","year":"2012","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.fertnstert.2014.04.028","article-title":"Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates","volume":"102","author":"Griffin","year":"2014","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B17","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/humrep\/deaa107","article-title":"GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study","volume":"35","author":"Haas","year":"2020","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B18","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMp048087","article-title":"Advanced maternal age\u2014how old is too old?","volume":"351","author":"Heffner","year":"2004","journal-title":"N Engl J Med"},{"key":"2022080105591424600_deac114-B19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.fertnstert.2012.01.130","article-title":"The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis","volume":"97","author":"Hill","year":"2012","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/humrep\/deh765","article-title":"GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF\/ICSI cycles: a prospective randomized study","volume":"20","author":"Humaidan","year":"2005","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.fertnstert.2008.12.042","article-title":"1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study","volume":"93","author":"Humaidan","year":"2010","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B22","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1093\/humrep\/det249","article-title":"GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients","volume":"28","author":"Humaidan","year":"2013","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0015-0282(16)54125-9","article-title":"Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization","volume":"55","author":"Imoedemhe","year":"1991","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.rbmo.2010.06.031","article-title":"LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango?","volume":"21","author":"Kol","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"2022080105591424600_deac114-B25","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1093\/humrep\/dei150","article-title":"A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists","volume":"20","author":"Kolibianakis","year":"2005","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/0974-1208.192056","article-title":"Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: a randomized control trial","volume":"9","author":"Krishna","year":"2016","journal-title":"J Hum Reprod Sci"},{"key":"2022080105591424600_deac114-B27","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.18632\/oncotarget.23916","article-title":"Dual trigger of triptorelin and HCG optimizes clinical outcome for high ovarian responder in GnRH-antagonist protocols","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"2022080105591424600_deac114-B28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12958-018-0451-x","article-title":"Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve","volume":"17","author":"Lin","year":"2019","journal-title":"Reprod Biol Endocrinol"},{"key":"2022080105591424600_deac114-B29","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.fertnstert.2013.07.1976","article-title":"Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles","volume":"100","author":"Lin","year":"2013","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1701-2163(16)35087-3","article-title":"Advanced reproductive age and fertility","volume":"33","author":"Liu","year":"2011","journal-title":"J Obstet Gynaecol Can"},{"key":"2022080105591424600_deac114-B31","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.fertnstert.2016.07.1068","article-title":"Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist","volume":"106","author":"Lu","year":"2016","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0015-0282(03)00173-0","article-title":"Use of recombinant human chorionic gonadotropin in ovulation induction","volume":"79","author":"Ludwig","year":"2003","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B33","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/humrep\/dex285","article-title":"Frozen embryo transfer: a review on the optimal endometrial preparation and timing","volume":"32","author":"Mackens","year":"2017","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ijgo.13405","article-title":"Comparative study between single versus dual trigger for poor responders in GnRH-antagonist ICSI cycles: a randomized controlled study","volume":"152","author":"Maged","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"2022080105591424600_deac114-B35","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/humrep\/deaa042","article-title":"The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation","volume":"35","author":"Maslow","year":"2020","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.fertnstert.2015.06.011","article-title":"Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles","volume":"104","author":"Meyer","year":"2015","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.fertnstert.2016.09.029","article-title":"Optimizing natural fertility: a committee opinion","volume":"107","author":"Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Reproductive Endocrinology and Infertility","year":"2017","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.fertnstert.2015.01.035","article-title":"Major drawbacks and additional benefits of agonist trigger\u2013not ovarian hyperstimulation syndrome related","volume":"103","author":"Shapiro","year":"2015","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B39","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.fertnstert.2011.03.109","article-title":"Comparison of \u201ctriggers\u201d using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin","volume":"95","author":"Shapiro","year":"2011","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B40","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.fertnstert.2010.09.009","article-title":"Efficacy of induced luteinizing hormone surge after \u201ctrigger\u201d with gonadotropin-releasing hormone agonist","volume":"95","author":"Shapiro","year":"2011","journal-title":"Fertil Steril"},{"key":"2022080105591424600_deac114-B41","first-page":"CD008046","article-title":"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology","volume":"10","author":"Youssef","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2022080105591424600_deac114-B42","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/humrep\/dex234","article-title":"The international glossary on infertility and fertility care, 2017","volume":"32","author":"Zegers-Hochschild","year":"2017","journal-title":"Hum Reprod"},{"key":"2022080105591424600_deac114-B43","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.rbmo.2017.09.002","article-title":"Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF\/ICSI cycles","volume":"35","author":"Zhang","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2022080105591424600_deac114-B44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ijgo.12457","article-title":"Comparison of dual trigger with combination GnRH agonist and hCG versus hCG alone trigger of oocyte maturation for normal ovarian responders","volume":"141","author":"Zhou","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"2022080105591424600_deac114-B45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/09513590.2014.978850","article-title":"Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes","volume":"31","author":"Zilberberg","year":"2015","journal-title":"Gynecol Endocrinol"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/8\/1795\/45197692\/deac114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/8\/1795\/45197692\/deac114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T02:00:24Z","timestamp":1659319224000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/37\/8\/1795\/6589878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,20]]},"published-print":{"date-parts":[[2022,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deac114","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,20]]}}}